Stacy W. Gray, MD, AM
Assistant Professor of Medicine, Harvard Medical School
Office phone: 617-632-3647
Preferred contact method: appointment phone
View Physician Profile
Population level cancer communication, Thoracic oncology, Cancer genetics
Area of Research
Thoracic Oncology, Cancer Genetics, Doctor-Patient Communication, Ethical and Social Issues in Genomics, Diffusion of Technology
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Dr. Gray received her MD from the University of Chicago Pritzker School of Medicine in 1999. She completed her residency in Internal Medicine and her fellowship in Hematology/Oncology at The University of Chicago Hospitals. While in fellowship, Dr. Gray also obtained a Masters degree in Public Policy from the University of Chicago Harris School. From 2005-2008 Dr. Gray worked in cancer communication research at the University of Pennsylvania. In 2008, she joined the faculty of the Dana-Farber Cancer Institute and the Brigham and Women's Hospital. Dr. Gray is a medical oncologist and cancer outcomes researcher in the Lowe Center for Thoracic Oncology and the division of Population Sciences.
ResearchThoracic Oncology, Cancer Genetics, Doctor-Patient Communication, Ethical and Social Issues in Genomics, Diffusion of Technology
Dr. Gray’s research focuses on understanding the social, ethical and medical outcomes related to the use of genomic technologies in cancer care. Her previous and ongoing work focuses on direct-to-consumer genetic testing, physician decision-making in areas of uncertainty, and cancer patient information seeking. Her work aims to understand the relationships between information dissemination, on an individual and population level, and the appropriate and inappropriate adoption of personalized cancer technologies. By studying the way in which information exposure relates to the uptake of genomic technologies and targeted therapies, Dr. Gray aims to understand if and how knowledge and uncertainty contribute to variations in cancer care. Dr. Gray leads a project that aims to establish a robust framework for the generation, interpretation, and clinical implementation of cancer whole-exome sequencing (WES). She and her colleagues are exploring the impact of the integration of somatic and germline WES on patients, oncologists, and institutional policies and practices. Through this work Dr. Gray examines the myriad ethical and social issues provoked by sequencing in cancer care in order to inform the design of systems that harness these emerging technologies and integrate them into high quality high impact cancer care.
- Gray SW, O’Grady C, Karp L, Smith D, Schwartz JS, Hornik R, Armstrong K. Risk information exposure and direct-to-consumer genetic testing for BRCA mutations among women with a personal or family history of breast or ovarian cancer. Cancer Epidemiol, Biomarkers and Prev. 2009 Apr; 18(4): 1303-11.
- Gray SW, Abel GA, Update on direct-to-consumer marketing in oncology, J Oncol Pract. 2012 Mar;8(2):124-7. Epub 2012 Feb 21.
- Gray SW, Hicks-Courant K, Lathan C, Garraway L, Park ER, Weeks JC. Attitudes of patients with cancer about personalized medicine and somatic genetic testing. J Oncol Pract 2012; Nov 1, 2012 (329-335) Epub 2012 August 7.
- Gray SW, Martins Y, Feuerman LZ, Bernhardt BA, Biesecker BB, Christensen KD, Joffe S, Rini C, Veenstra D, McGuire AL, Social and behavioral research in genomic sequencing: approaches from the Clinical Sequencing Exploratory Research Consortium Outcomes and Measures Working Group, Genet Med, in press.
- Gray SW, Hicks-Courant K, Cronin A, Rollins B, Weeks JC, Physicians' attitudes about multiplex tumor genomic testing, J Clin Oncol, in press.